Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.
Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
Serum Institute exits IXCHIQ rollout as Valneva resets LMIC strategy
Valneva ends its chikungunya vaccine deal with Serum Institute of India. Find out what this means for Asian access, LMIC rollout, and CEPI commitments.